Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in ...

Preliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are typically unresponsive to pembrolizumab, such as non-small cell lung cancer

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,United States ,Virginia ,Chad ,American ,Jeff Jones ,Rose Weldon ,Jeffrey Jones ,Alexander Spira ,Linkedin ,Development Plan ,American Society Of Clinical Oncology ,Exchange Commission ,Cullinan Therapeutics Inc ,Virginia Cancer Specialists Research Institute ,Nasdaq ,Clinical Oncology ,Annual Meeting ,Key Clinical Results ,Combination Arm ,Combination Cohorts ,Updated Key Clinical Results ,Chief Medical Officer ,Olive Investor ,Investor Event ,Cullinan Therapeutics ,Chad Messer ,Private Securities Litigation Reform Act ,Annual Report ,